Sponsors of testosterone replacement therapies should be required to conduct randomized controlled trials to further assess a potential cardiovascular risk, FDA advisors said Sept. 17.
Safety and efficacy trials should also be conducted if companies want to claim an indication for age-related hypogonadism conventionally known as “Low-T,” the majority of the joint panel of FDA’s Bone, Reproductive and Urologic Drugs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?